494 related articles for article (PubMed ID: 15940147)
21. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Frankel A; Sohn A; Patel RV; Lebwohl M
J Drugs Dermatol; 2011 Jun; 10(6):666-72. PubMed ID: 21637908
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.
Wolff K; Fleming C; Hanifin J; Papp K; Reitamo S; Rustin M; Shear N; Silny W; Korman N; Marks I; Cherill R; Emady-Azar S; Paul C;
Br J Dermatol; 2005 Jun; 152(6):1296-303. PubMed ID: 15948996
[TBL] [Abstract][Full Text] [Related]
23. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis.
Sigurgeirsson B; Ho V; Ferrándiz C; Andriano K; Grinienko A; Jimenez P;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1290-301. PubMed ID: 18624866
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
26. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment.
Simon D; Vassina E; Yousefi S; Kozlowski E; Braathen LR; Simon HU
J Allergy Clin Immunol; 2004 Oct; 114(4):887-95. PubMed ID: 15480330
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.
Schwarz T; Kreiselmaier I; Bieber T; Thaci D; Simon JC; Meurer M; Werfel T; Zuberbier T; Luger TA; Wollenberg A; Bräutigam M
J Am Acad Dermatol; 2008 Jul; 59(1):34-40. PubMed ID: 18462835
[TBL] [Abstract][Full Text] [Related]
28. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
29. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
[TBL] [Abstract][Full Text] [Related]
30. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C; Ling M; Lebwohl M; Pariser D; Draelos Z; Gottlieb AB; Zaias N; Chen DM; Parneix-Spake A; Hultsch T; Menter A
J Am Acad Dermatol; 2004 Nov; 51(5):731-8. PubMed ID: 15523351
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT.
Bauer A; Lange N; Matterne U; Meurer M; Braeutigam M; Diepgen TL
J Dtsch Dermatol Ges; 2012 Jun; 10(6):426-33. PubMed ID: 22112014
[TBL] [Abstract][Full Text] [Related]
32. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
33. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
Spergel JM; Boguniewicz M; Paller AS; Hebert AA; Gallagher PR; McCormick C; Parneix-Spake A; Hultsch T
Br J Dermatol; 2007 Aug; 157(2):378-81. PubMed ID: 17573885
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
35. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
36. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.
Cicek D; Kandi B; Bakar S; Turgut D
J Dermatolog Treat; 2009; 20(6):344-9. PubMed ID: 19954391
[TBL] [Abstract][Full Text] [Related]
37. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
38. Pimecrolimus: a review of pre-clinical and clinical data.
Graham-Brown RA; Grassberger M
Int J Clin Pract; 2003 May; 57(4):319-27. PubMed ID: 12800465
[TBL] [Abstract][Full Text] [Related]
39. Pimecrolimus 1% cream (Elidel) for atopic dermatitis.
Bernard LA; Bergman JN; Eichenfield LF
Skin Therapy Lett; 2002 Apr; 7(4):1-3. PubMed ID: 12097994
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.
Siegfried E; Korman N; Molina C; Kianifard F; Abrams K
J Dermatolog Treat; 2006; 17(3):143-50. PubMed ID: 16854753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
